Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Kyorin, Sagami report antineoplastic acrylamides

Aug. 16, 1996

Pola claims antisense oligonucleotides for cancer

Aug. 16, 1996

Mitsui Toatsu claims potential antitumor agents

Aug. 16, 1996

GEM-230 in preclinical testing at Hybridon

Aug. 16, 1996

ISIS-3521/CGP-64128A efficacy shown in preclinical models

Aug. 16, 1996

MAM-102: antineoplastic protein tyrosine kinase inhibitor

Aug. 16, 1996

Letrozole approved for marketing in France

Aug. 16, 1996

Sanofi Winthrop discloses topoisomerase II inhibitors

Aug. 16, 1996

Guilford to develop anticancer drugs in biodegradable polymers

Aug. 16, 1996

SuperGen acquires marketing rights for Barr generic drugs

Aug. 16, 1996

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 14, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...